Bastion Asset Management Inc. Makes New Investment in Bruker Corporation $BRKR

Bastion Asset Management Inc. acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR) during the first quarter, Holdings Channel reports. The fund acquired 21,471 shares of the medical research company’s stock, valued at approximately $777,000.

A number of other hedge funds have also recently made changes to their positions in BRKR. Royal Bank of Canada raised its holdings in Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after buying an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Bruker during the first quarter worth about $262,000. Goldman Sachs Group Inc. grew its holdings in Bruker by 107.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after buying an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Bruker by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock valued at $15,285,000 after purchasing an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth boosted its position in shares of Bruker by 115.0% during the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after buying an additional 6,008 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BRKR. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Leerink Partners increased their price objective on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. TD Cowen reiterated a “hold” rating on shares of Bruker in a report on Wednesday. JPMorgan Chase & Co. raised their price target on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Finally, Guggenheim raised their price target on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $56.79.

Bruker Trading Up 1.0%

BRKR opened at $59.25 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The firm’s fifty day moving average price is $54.44 and its 200 day moving average price is $45.81. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $64.54. The stock has a market capitalization of $9.02 billion, a PE ratio of -246.88, a P/E/G ratio of 1.88 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. During the same quarter last year, the business earned $0.47 earnings per share. Bruker’s revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Monday, June 22nd. Bruker’s payout ratio is currently -83.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.